A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Recruiting now Phase 1/2 NCT06988488
Run by Celgene · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Who can join (things the study team will check)
✅ You may be able to join if…
- Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2).
- Measurable MM by local laboratory.
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
- Adherence to contraception requirements.
🚫 You may not be able to join if…
- Prior treatment with mezigdomide.
- Prior treatment with T cell engaging or T cell engager (TCE).
- Prior treatment with B cell-maturation antigen (BCMA)-targeting therapy, with the exception of participants who have received autologous BCMA-targeted CART-cell therapy> 6 months from the start of study therapy
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
- Local Institution - 0026, Vancouver, British Columbia, Canada
- QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Local Institution - 0030, Suzhou, Jiangsu, China
- Local Institution - 0031, Shanghai, Shanghai Municipality, China
- Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Germany
- Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
+ 10 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06988488.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.